On Tuesday, Prime Medicine Inc (NASDAQ: PRME) was unchanged from the session before settling in for the closing price of $3.22. A 52-week range for PRME has been $2.85 – $9.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -25.00%. When this article was written, the company’s average yearly earnings per share was at 21.99%. With a float of $50.89 million, this company’s outstanding shares have now reached $131.16 million.
The extent of productivity of a business whose workforce counts for 234 workers is very important to gauge. In terms of profitability, gross margin is 98.47%, operating margin of -586.63%, and the pretax margin is -568.39%.
Prime Medicine Inc (PRME) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Prime Medicine Inc stocks. The insider ownership of Prime Medicine Inc is 61.20%, while institutional ownership is 36.06%. The most recent insider transaction that took place on Feb 15 ’24, was worth 20,000,000. In this transaction Director of this company bought 3,200,000 shares at a rate of $6.25, taking the stock ownership to the 3,200,000 shares. Before that another transaction happened on Feb 15 ’24, when Company’s 10% Owner bought 3,200,000 for $6.25, making the entire transaction worth $20,000,000. This insider now owns 3,200,000 shares in total.
Prime Medicine Inc (PRME) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.99% per share during the next fiscal year.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
You can see what Prime Medicine Inc (PRME) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 527.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.01, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.34 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
The latest stats from [Prime Medicine Inc, PRME] show that its last 5-days average volume of 1.25 million was superior to 1.0 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 50.25%. Additionally, its Average True Range was 0.27.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 11.94%, which indicates a significant decrease from 54.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.10% in the past 14 days, which was higher than the 79.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.68, while its 200-day Moving Average is $5.20. Now, the first resistance to watch is $3.35. This is followed by the second major resistance level at $3.49. The third major resistance level sits at $3.58. If the price goes on to break the first support level at $3.13, it is likely to go to the next support level at $3.04. The third support level lies at $2.91 if the price breaches the second support level.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
There are 131,161K outstanding shares of the company, which has a market capitalization of 422.34 million. As of now, sales total 0 K while income totals -198,130 K. Its latest quarter income was 210 K while its last quarter net income were -52,520 K.
